SecBot SecBot
SECBOTREPLAY Home › Report › TLX

TLX · Telix reported Q2 2026 revenue of $247M, up 21% YoY and 7% QoQ, driven…

Telix Pharmaceuticals Limited · PRESS-RELEASE filed Jul 20, 2026 at 19:31 ET

At the news

BULLISHIMPACT 6/10

PRESS-RELEASE filed Jul 20, 2026 at 19:31 ET

Telix reported Q2 2026 revenue of $247M, up 21% YoY and 7% QoQ, driven by Precision Medicine growth. The company expects FY 2026 revenue and other income to exceed $1B, tracking the upper end of guidance. R&D guidance was raised to $230-270M to accelerate pipeline programs, and a $600M convertible bond refinancing was completed.

  • Q2 2026 revenue $247M, up 21% YoY and 7% QoQ
  • Precision Medicine revenue $202M, up 30% YoY and 9% QoQ
  • FY 2026 revenue guidance tracking upper end of $950M-$970M, plus $40M non-refundable Regeneron payment
  • R&D expenditure guidance raised to $230M-$270M

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access